US 12,305,228 B2
Inhibition-resistant polymerases
Milko B. Kermekchiev, St. Louis, MO (US); and Zhian Zhang, Ballwin, MO (US)
Assigned to DNA POLYMERASE TECHNOLOGY, INC., St. Louis, MO (US)
Filed by DNA Polymerase Technology, Inc., St. Louis, MO (US)
Filed on Jun. 15, 2020, as Appl. No. 16/901,101.
Application 16/901,101 is a division of application No. 14/055,796, filed on Oct. 16, 2013, granted, now 10,683,537.
Claims priority of provisional application 61/811,611, filed on Apr. 12, 2013.
Claims priority of provisional application 61/714,671, filed on Oct. 16, 2012.
Prior Publication US 2021/0147908 A1, May 20, 2021
Int. Cl. C12Q 1/686 (2018.01); C12N 9/12 (2006.01)
CPC C12Q 1/686 (2013.01) [C12N 9/1252 (2013.01)] 9 Claims
OG exemplary drawing
 
1. An isolated DNA polymerase comprising a polypeptide sequence having at least 95% sequence identity to positions 279 through 832 of SEQ ID NO: 1, and further comprising the amino acid substitution D732N,
wherein the D732N amino acid substitution is relative to SEQ ID NO: 1, and wherein the isolated polypeptide has DNA polymerase activity in the presence of an inhibitory substance in an amount sufficient to cause a wild-type Taq polymerase comprising SEQ ID NO: 1 to fail to amplify a target nucleic acid in a polymerase chain reaction (PCR), and wherein the inhibitor comprises one or more of chocolate, plant material. blood, a blood fraction, or humic acid.